Logo image of VIVS

VIVOSIM LABS INC (VIVS) Stock Fundamental Analysis

USA - NASDAQ:VIVS - US68620A3023 - Common Stock

3.34 USD
-0.11 (-3.19%)
Last: 9/26/2025, 10:59:56 AM
Fundamental Rating

4

Taking everything into account, VIVS scores 4 out of 10 in our fundamental rating. VIVS was compared to 538 industry peers in the Biotechnology industry. While VIVS has a great health rating, there are worries on its profitability. VIVS has a decent growth rate and is not valued too expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

VIVS had positive earnings in the past year.
VIVS had a negative operating cash flow in the past year.
VIVS had negative earnings in each of the past 5 years.
VIVS had a negative operating cash flow in each of the past 5 years.
VIVS Yearly Net Income VS EBIT VS OCF VS FCFVIVS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -10M -20M -30M

1.2 Ratios

With a decent Return On Assets value of -16.59%, VIVS is doing good in the industry, outperforming 79.74% of the companies in the same industry.
VIVS's Return On Equity of -20.83% is amongst the best of the industry. VIVS outperforms 84.01% of its industry peers.
Industry RankSector Rank
ROA -16.59%
ROE -20.83%
ROIC N/A
ROA(3y)-111.01%
ROA(5y)-81.92%
ROE(3y)-181.24%
ROE(5y)-124.91%
ROIC(3y)N/A
ROIC(5y)N/A
VIVS Yearly ROA, ROE, ROICVIVS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -100 -200 -300 -400

1.3 Margins

With an excellent Gross Margin value of 97.89%, VIVS belongs to the best of the industry, outperforming 97.21% of the companies in the same industry.
VIVS's Gross Margin has improved in the last couple of years.
VIVS does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 97.89%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y2.58%
VIVS Yearly Profit, Operating, Gross MarginsVIVS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -2K -4K -6K -8K -10K

More info and screens

7

2. Health

2.1 Basic Checks

VIVS does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for VIVS has been reduced compared to 1 year ago.
VIVS has less shares outstanding than it did 5 years ago.
There is no outstanding debt for VIVS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
VIVS Yearly Shares OutstandingVIVS Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2M 4M 6M 8M 10M
VIVS Yearly Total Debt VS Total AssetsVIVS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M

2.2 Solvency

Based on the Altman-Z score of -40.70, we must say that VIVS is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of VIVS (-40.70) is worse than 91.64% of its industry peers.
There is no outstanding debt for VIVS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -40.7
ROIC/WACCN/A
WACC9.87%
VIVS Yearly LT Debt VS Equity VS FCFVIVS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20M -20M 40M 60M

2.3 Liquidity

A Current Ratio of 4.52 indicates that VIVS has no problem at all paying its short term obligations.
VIVS has a Current ratio (4.52) which is comparable to the rest of the industry.
VIVS has a Quick Ratio of 4.52. This indicates that VIVS is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of VIVS (4.52) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 4.52
Quick Ratio 4.52
VIVS Yearly Current Assets VS Current LiabilitesVIVS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 297.92% over the past year.
VIVS shows a strong growth in Revenue. In the last year, the Revenue has grown by 94.52%.
Measured over the past years, VIVS shows a very negative growth in Revenue. The Revenue has been decreasing by -42.03% on average per year.
EPS 1Y (TTM)297.92%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-397.81%
Revenue 1Y (TTM)94.52%
Revenue growth 3Y-54.21%
Revenue growth 5Y-42.03%
Sales Q2Q%-5.13%

3.2 Future

Based on estimates for the next years, VIVS will show a decrease in Earnings Per Share. The EPS will decrease by -6.30% on average per year.
VIVS is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 16.82% yearly.
EPS Next Y2.6%
EPS Next 2Y-6.3%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year18.24%
Revenue Next 2Y16.82%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
VIVS Yearly Revenue VS EstimatesVIVS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2022 2023 2024 2025 2026 2027 1M 2M 3M 4M
VIVS Yearly EPS VS EstimatesVIVS Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2024 2025 2026 2027 -20 -40 -60 -80 -100

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

VIVS is valuated cheaply with a Price/Earnings ratio of 1.21.
VIVS's Price/Earnings ratio is rather cheap when compared to the industry. VIVS is cheaper than 99.63% of the companies in the same industry.
The average S&P500 Price/Earnings ratio is at 27.06. VIVS is valued rather cheaply when compared to this.
The Forward Price/Earnings Ratio is negative for VIVS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE 1.21
Fwd PE N/A
VIVS Price Earnings VS Forward Price EarningsVIVS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
VIVS Per share dataVIVS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 -4

4.3 Compensation for Growth

VIVS's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A cheap valuation may be justified as VIVS's earnings are expected to decrease with -6.30% in the coming years.
PEG (NY)0.47
PEG (5Y)N/A
EPS Next 2Y-6.3%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

VIVS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

VIVOSIM LABS INC

NASDAQ:VIVS (9/26/2025, 10:59:56 AM)

3.34

-0.11 (-3.19%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-19 2025-02-19/bmo
Earnings (Next)N/A N/A
Inst Owners2.58%
Inst Owner ChangeN/A
Ins Owners0.6%
Ins Owner ChangeN/A
Market Cap8.68M
Analysts45.71
Price TargetN/A
Short Float %1.48%
Short Ratio0.1
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-7.06%
Min Revenue beat(2)-22.82%
Max Revenue beat(2)8.7%
Revenue beat(4)1
Avg Revenue beat(4)-22.23%
Min Revenue beat(4)-46.52%
Max Revenue beat(4)8.7%
Revenue beat(8)2
Avg Revenue beat(8)-39.63%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE 1.21
Fwd PE N/A
P/S 61.15
P/FCF N/A
P/OCF N/A
P/B 0.91
P/tB 0.91
EV/EBITDA N/A
EPS(TTM)2.75
EY82.34%
EPS(NY)-0.89
Fwd EYN/A
FCF(TTM)-4.01
FCFYN/A
OCF(TTM)-4.01
OCFYN/A
SpS0.05
BVpS3.67
TBVpS3.67
PEG (NY)0.47
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -16.59%
ROE -20.83%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 97.89%
FCFM N/A
ROA(3y)-111.01%
ROA(5y)-81.92%
ROE(3y)-181.24%
ROE(5y)-124.91%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y2.58%
F-Score5
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.52
Quick Ratio 4.52
Altman-Z -40.7
F-Score5
WACC9.87%
ROIC/WACCN/A
Cap/Depr(3y)52.61%
Cap/Depr(5y)295.14%
Cap/Sales(3y)51.89%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)297.92%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-397.81%
EPS Next Y2.6%
EPS Next 2Y-6.3%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)94.52%
Revenue growth 3Y-54.21%
Revenue growth 5Y-42.03%
Sales Q2Q%-5.13%
Revenue Next Year18.24%
Revenue Next 2Y16.82%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y14.96%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y33.39%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y31.95%
OCF growth 3YN/A
OCF growth 5YN/A